Jiangsu Runheng Pharmaceutical

Jiangsu Runheng Pharmaceutical is a key subsidiary of Jiangsu Hengrui Pharmaceuticals, one of China's largest and most prominent pharmaceutical companies. Based in Lianyungang, the company operates as a major research, development, and manufacturing center for the Hengrui group, focusing on innovative drugs and high-end generics. Its portfolio spans multiple therapeutic areas, including oncology, anesthesiology, and metabolic diseases, with a strong emphasis on small molecule and biologic development. The company maintains state-of-the-art, GMP-compliant facilities that support the global clinical development and commercialization of Hengrui's pipeline. As a core component of its parent company's infrastructure, Runheng is instrumental in advancing therapies like camrelizumab and pyrotinib through the regulatory landscape. The facility is also involved in the production of critical APIs and finished dosage forms for both domestic and international markets.